摘要
目的:研究百奥蚓激酶联合阿托伐他汀钙对缺血性脑血管病患者颈动脉内膜中层厚度(IMT)的影响。方法:将缺血性脑血管病患者68例,随机分为实验组(34例)和对照组(34例),对照组使用阿托伐他汀钙,20mg,每日一次;实验组在对照组基础上,加用百奥蚓激酶60U,每日3次,治疗12个月,比较两组IMT、纤维蛋白原、纤溶酶原激活剂、血小板聚集率、血粘度指标、空腹血糖及血脂水平。结果:实验组治疗12个月后,颈动脉IMT、纤维蛋白原、纤溶酶原、血小板聚集率、全血低切、TG、TC、LPL-C均显著降低,治疗后的IMT(0.74±0.05)mm与治疗前(0.95±0.07)mm及对照组治疗前后的IMT(0.96±0.05)mm(0.83±0.06)mm比较、差异均有统计学意义(P【0.05)。两组间血糖比较差异无统计学意义。结论:缺血性脑血管病患者服用百奥蚓激酶联合阿托伐他汀钙治疗能更好地延缓颈动脉IMT进展。
Objective:To study the effect of combination of lumbrokinase and atorvastatin on carotid artery intima-media thickness (IMT)in patients with ischemic cerebrovascular disease.Methods:Sixty-eight patients with ischemic cerebrovascular disease were randomly divided into test and control groups.The control group was treated with atorvastatin and the test group was treated with atorvastatin 20mg every night in addition to lumbrokinase for twelve months.The differences were observed between two groups. Results:After twelve months of therapy, in test group, carotid artery IMT、fibrinogen、Tissue-type Plasminogen Activator、Platelet Aggregation Rate、viscosity、serum triglyceride、 total cholesterol and low-density lipoprotein cholesterol significantly decreased.There were significant difference pre-treatment and after treatment,and significant differences between test group and control group.Conclusion:The combination of lumbrokinase and atorvastatin can delay increase in carotid artery intima-media thickness of patients with ischemic cerebrovascular disease.
出处
《临床医药实践》
2009年第4Z期1533-1535,共3页
Proceeding of Clinical Medicine
关键词
缺血性脑血管病
动脉硬化
百奥蚓激酶
血管内膜
阿托伐他汀
ischemic cerebrovascular disease
arterioscle rosis
lumbrokinase
tunica intima
atrovastatin .
